Skip to main content

Summary

for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion:

Description

Summary

This two-part, part 1: open-label extension (OLE) and part 2: safety monitoring (SM) study will examine the efficacy and safety of continued etrolizumab treatment in moderate to severe ulcerative colitis (UC) participants previously enrolled in etrolizumab Phase II/III studies. Participants with moderate to severe UC who were enrolled in the Phase II OLE study (GA27927 [NCT01461317]) or the Phase III studies (GA28948 [NCT02163759], GA28949 [NCT02171429], GA28950 [NCT02100696], GA29102 [NCT02165215], and GA29103 [NCT02136069]) were included. Participants from the Phase II OLE study or the Phase III studies who are not eligible or willing to receive etrolizumab in the OLE-SM study, and who have completed the 12-week safety follow-up period will be enrolled in Part 2. Part 1 of OLE-SM will continue for up to 7 years after the first participant is enrolled into the study. Following Part 1, participants will enter Part 2 for a period of 92 weeks.

Official Title

An Open-Label Extension and Safety Monitoring Study of Moderate to Severe Ulcerative Colitis Patients Previously Enrolled in Etrolizumab Phase II/III Studies

Keywords

Ulcerative Colitis Colitis Ulcer Colitis, Ulcerative

Eligibility

You can join if…

Open to people ages 18 years and up

Part 1 (Open-label Extension)

  • Participants previously enrolled in the Phase II OLE study or Phase III controlled studies who meet the eligibility criteria for open-label etrolizumab for those studies as described in the protocol

Part 2 (Safety Monitoring)

  • Participants whose safety follow-up or PML follow-up is not completed within Study GA27927 and participants who had their last dose of etrolizumab in July 2016 in Study GA27927 and are not eligible or willing to enroll in Part 1 (OLE)
  • Participants who participated in one of the etrolizumab Phase III studies and are not eligible or willing to enter Part 1 (OLE)
  • Participants who transfer from Part 1 (OLE)
  • Completion of the 12-week safety follow-up prior to entering.

You CAN'T join if...

Part 1 (Open-label Extension)

  • Withdrawal of consent from and participant not compliant in the Phase II OLE study or any of the Phase III studies
  • Participant who discontinued etrolizumab/etrolizumab placebo prior to Week 10 or did not perform the Week 10 visit of the Phase III Studies GA28948, GA28949, GA29102, and GA29103
  • Participant who discontinued etrolizumab/etrolizumab placebo prior to Week 14 or did not perform the Week 14 visit of the Phase III Study GA28950
  • Any new, significant, uncontrolled condition

Locations

  • University of California at San Francisco accepting new patients
    San Francisco, California, 94115, United States
  • Uni. of California at San Francisco; Dept Pediatric, Div. of Gastroenterology, Hepatology & Nutri accepting new patients
    San Francisco, California, 94158, United States
  • Digestive Care Associates, A Medical Corporation withdrawn
    San Carlos, California, 94070, United States
  • Sutter Gould Medical Foundation withdrawn
    Modesto, California, 95355, United States
  • Sutter Institute for Medical Research withdrawn
    Roseville, California, 95661, United States
  • Ventura Clinical Trials accepting new patients
    Ventura, California, 93003, United States
  • Facey Medical Group withdrawn
    Mission Hills, California, 91345, United States
  • Gastrointestinal Bioscience withdrawn
    Los Angeles, California, 90067, United States
  • Santa Monica Research Institute withdrawn
    Santa Monica, California, 90404, United States
  • UCLA Medical Center withdrawn
    Los Angeles, California, 90095, United States
  • Digestive and Liver Disease Specialists; A Medical Group, Inc. withdrawn
    Garden Grove, California, 92840, United States
  • Community Clinical Trials withdrawn
    Orange, California, 92868, United States
  • University of California, Irvine Medical Center accepting new patients
    Orange, California, 92868, United States
  • Therapeutic Research Institute of Orange County withdrawn
    Laguna Hills, California, 92653, United States
  • Las Vegas Medical Research not yet accepting patients
    Las Vegas, Nevada, 89113, United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Hoffmann-La Roche
ID
NCT02118584
Phase
Phase 3
Lead Scientist
Melvin Heyman
Study Type
Interventional
Last Updated
November 14, 2017
I’m interested in this study!